Toxoplasma endocytosis of host cytoplasm

弓形虫对宿主细胞质的内吞作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Innate immune defenses help restrict growth of the protozoan pathogen Toxoplasma gondii, but their efficacy is offset by parasite counter defenses. For example, infected macrophages attempt to destroy the parasite by expressing immunity-related GTPases (IRGs) that load onto and dismantle the parasitophorous membrane, but the parasite thwarts this by phosphorylating Irg proteins to diminish their activity. Since phosphorylation is a reversible, and therefore temporary, we hypothesize that T. gondii additionally eliminates these host effector proteins permanently by internalizing them into its endocytic system. Our recent unexpected finding that the parasite readily internalizes a reporter protein expressed in the host cytosol supports this hypothesis. Further, the reporter protein is most abundantly seen in protease-deficient parasites, suggesting that internalized host proteins are normally digested in the parasite endocytic system. Also, parasites deficient in the biogenesis of tubular membranes within the parasitophorous vacuole are unable to efficiently internalize the reporter protein, indicating that the tubular membranes are required for uptake. These deficient parasites are also highly susceptible to killing by activated macrophages. The specific aims are to: (1) confirm the parasite endocytic system as the destination of internalized proteins; and (2) show that Toxoplasma uses the intravacuolar network of tubular membranes to internalize IRGs for destruction in its endolysosomal system. We expect to show that the parasite eliminates IRGs by endocytosis and degradation as an immune evasion strategy. The work is anticipated to open exciting new opportunities to diminish parasite intracellular survival during infection.
描述(由申请人提供):先天免疫防御有助于限制原生动物病原体弓形虫的生长,但其功效被寄生虫的反防御抵消。例如,受感染的巨噬细胞试图通过表达免疫相关的GTP酶(IRG)来破坏寄生虫,这些GTP酶装载并拆除寄生虫膜,但寄生虫通过磷酸化Irg蛋白质以降低其活性来阻止这一点。由于磷酸化是可逆的,因此是暂时的,我们假设T。弓形虫还通过将这些宿主效应蛋白内化到其内吞系统中而永久地消除这些宿主效应蛋白。我们最近意外的发现,寄生虫很容易内化宿主胞质中表达的报告蛋白支持这一假设。此外,报告蛋白是最丰富的蛋白酶缺陷型寄生虫,这表明内化的宿主蛋白通常在寄生虫内吞系统消化。此外,寄生虫缺乏在寄生虫液泡内的管状膜的生物发生是无法有效地内化的报告蛋白,这表明需要的管状膜的摄取。这些缺陷型寄生虫也极易被活化的巨噬细胞杀死。具体目标是:(1)证实寄生虫内吞系统是内化蛋白的目的地;(2)表明弓形虫使用管状膜的液泡内网络内化IRG,以破坏其内溶酶体系统。我们希望表明,寄生虫消除IRGs的内吞作用和降解作为一种免疫逃避策略。这项工作有望为减少寄生虫在感染过程中的细胞内存活开辟令人兴奋的新机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Vernon Bruce Carruthers其他文献

Vernon Bruce Carruthers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Vernon Bruce Carruthers', 18)}}的其他基金

Identifying novel players in Toxoplasma autophagy during chronic infection”
识别慢性感染期间弓形虫自噬的新参与者 –
  • 批准号:
    10223735
  • 财政年份:
    2021
  • 资助金额:
    $ 19.44万
  • 项目类别:
Identifying novel players in Toxoplasma autophagy during chronic infection”
识别慢性感染期间弓形虫自噬的新参与者 –
  • 批准号:
    10372165
  • 财政年份:
    2021
  • 资助金额:
    $ 19.44万
  • 项目类别:
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis
中枢神经系统渗透性组织蛋白酶 L 抑制剂治疗慢性弓形虫病的合理设计
  • 批准号:
    9813831
  • 财政年份:
    2016
  • 资助金额:
    $ 19.44万
  • 项目类别:
Parasite autophagy as a key survival mechanism for the AIDS-associated pathogen Toxoplasma gondii
寄生虫自噬是艾滋病相关病原体弓形虫的关键生存机制
  • 批准号:
    10296195
  • 财政年份:
    2015
  • 资助金额:
    $ 19.44万
  • 项目类别:
Parasite autophagy as a key survival mechanism for the AIDS-associated pathogen Toxoplasma gondii
寄生虫自噬是艾滋病相关病原体弓形虫的关键生存机制
  • 批准号:
    10669199
  • 财政年份:
    2015
  • 资助金额:
    $ 19.44万
  • 项目类别:
T. GONDII CHLOROQUINE RESISTANCE TRANSPORTER AND REDOX
弓形虫氯喹抗性转运蛋白和氧化还原
  • 批准号:
    8938727
  • 财政年份:
    2015
  • 资助金额:
    $ 19.44万
  • 项目类别:
Parasite autophagy as a key survival mechanism for the AIDS-associated pathogen Toxoplasma gondii
寄生虫自噬是艾滋病相关病原体弓形虫的关键生存机制
  • 批准号:
    10461953
  • 财政年份:
    2015
  • 资助金额:
    $ 19.44万
  • 项目类别:
Toxoplasma endocytosis of host cytoplasm
弓形虫对宿主细胞质的内吞作用
  • 批准号:
    8604674
  • 财政年份:
    2013
  • 资助金额:
    $ 19.44万
  • 项目类别:
Proteolytic modulation of toxoplasma invasion proteins
弓形虫入侵蛋白的蛋白水解调节
  • 批准号:
    8384858
  • 财政年份:
    2008
  • 资助金额:
    $ 19.44万
  • 项目类别:
Proteolytic modulation of toxoplasma invasion proteins
弓形虫入侵蛋白的蛋白水解调节
  • 批准号:
    7579559
  • 财政年份:
    2008
  • 资助金额:
    $ 19.44万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 19.44万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了